# A Study of Elpipodect (MK-8189) in Participants With Bipolar I Disorder (MK-8189-020)

> **NCT06273774** · PHASE1 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 34 (actual)

## Conditions studied

- Bipolar I Disorder

## Interventions

- **DRUG:** Elpipodect
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06273774
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-04-08
- **Primary completion:** 2024-08-21
- **Final completion:** 2024-08-21
- **Target enrollment:** 34 (ACTUAL)
- **Last updated:** 2026-04-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06273774

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06273774, "A Study of Elpipodect (MK-8189) in Participants With Bipolar I Disorder (MK-8189-020)". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT06273774. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*